Metabolic inhibitors impose selection pressures favoring tumor subclones with compensatory pathways, such as FAS upregulation during cholesterol blockade or the maintenance of epigenetic “memory” of immunosuppressive programming by TAMs. Here, FAS is linked to neoplasm.